Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti–PD–1 antibody

BACKGROUND: Conversion therapy is feasible in patients with oncologically unresectable hepatocellular carcinoma (HCC). However, it is challenging to prospectively identify patients who are more likely to achieve successful conversion before initiating systemic therapy, either alone or combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bin, Zhu, Xiao-Dong, Shen, Ying-Hao, Zhu, Jin-Jin, Liu, Jie, Li, Mei-Ling, Tang, Pei-Wen, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan, Huang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732007/
https://www.ncbi.nlm.nih.gov/pubmed/36505445
http://dx.doi.org/10.3389/fimmu.2022.1016736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732007/
https://www.ncbi.nlm.nih.gov/pubmed/36505445
http://dx.doi.org/10.3389/fimmu.2022.1016736

Ejemplares similares